Institute Collection and Analysis of Nanobodies (iCAN): a Comprehensive Database and Analysis Platform for Nanobodies

Overview

Journal BMC Genomics

Publisher Biomed Central

Specialty Genetics

Date 2017 Oct 19

PMID 29041922

Citations 20

Authors

Jing Zuo

Jian Li

Rongxin Zhang

Longsheng Xu

Hanhan Chen

Xiaohuan Jia

Zhipeng Su

Linhong Zhao

Xing Huang

Wei Xie

Affiliations

Soon will be listed here.

Abstract

Background: Nanobodies are single-domain antibodies that contain the unique structural and functional properties of naturally-occurring heavy chain in camelidae. As a novel class of antibody, they show many advantages compared with traditional antibodies such as smaller size, higher stability, improved specificity, more easily expressed in microorganisms. These unusual hallmarks make them as promising tools in basic research and clinical practice. Although thousands of nanobodies are known to be published, no single database provides searchable, unified annotation and integrative analysis tools for these various nanobodies.

Results: Here, we present the database of Institute Collection and Analysis of Nanobodies (iCAN). It is built for the aim that addressing the above gap to expand and accelerate the nanobody research. iCAN, as the first database of nanobody, contains the most comprehensive information to date on nanobodies and related antigens. So far, iCAN incorporates 2391 entries which include 2131 from patents and 260 from publications and provides a simple user interface for researchers to retrieve and view the detailed information of nanobodies. In addition to the data collection, iCAN also provides online bioinformatic tools for sequence analysis and characteristic feature extraction.

Conclusions: In summary, iCAN enables researchers to analyze nanobody features and explore the applications of nanobodies more efficiently. iCAN is freely available at http://ican.ils.seu.edu.cn .

Citing Articles

Unveiling the new chapter in nanobody engineering: advances in traditional construction and AI-driven optimization.

Liu J, Wu L, Xie A, Liu W, He Z, Wan Y J Nanobiotechnology. 2025; 23(1):87.

PMID: 39915791 PMC: 11800653. DOI: 10.1186/s12951-025-03169-5.

NanoB to monitor interactions of ligands with membrane proteins by combining nanobodies and NanoBRET.

van den Bor J, Bergkamp N, Anbuhl S, Dekker F, Comez D, Perez Almeria C Cell Rep Methods. 2023; 3(3):100422.

PMID: 37056381 PMC: 10088090. DOI: 10.1016/j.crmeth.2023.100422.

NbThermo: a new thermostability database for nanobodies.

Valdes-Tresanco M, Valdes-Tresanco M, Molina-Abad E, Moreno E Database (Oxford). 2023; 2023.

PMID: 37042467 PMC: 10091358. DOI: 10.1093/database/baad021.

General Trends of the Antibody VHs Domain Dynamics.

Vattekatte A, Diharce J, Rebehmed J, Cadet F, Gardebien F, Etchebest C Int J Mol Sci. 2023; 24(5).

PMID: 36901942 PMC: 10003728. DOI: 10.3390/ijms24054511.

Development of Synthetic mRNAs Encoding Split Cytotoxic Proteins for Selective Cell Elimination Based on Specific Protein Detection.

Free K, Nakanishi H, Itaka K Pharmaceutics. 2023; 15(1).

PMID: 36678842 PMC: 9867180. DOI: 10.3390/pharmaceutics15010213.

References

Leduc C, Si S, Gautier J, Gao Z, Shibu E, Gautreau A . Single-molecule imaging in live cell using gold nanoparticles. Methods Cell Biol. 2015; 125:13-27. DOI: 10.1016/bs.mcb.2014.10.002. View

Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U . Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011; 25(7):2433-46. DOI: 10.1096/fj.10-180331. View

Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken L . Single-domain antibody fragments with high conformational stability. Protein Sci. 2002; 11(3):500-15. PMC: 2373476. DOI: 10.1110/ps.34602. View

Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, HOLZER W, De Genst E . Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998; 17(13):3512-20. PMC: 1170688. DOI: 10.1093/emboj/17.13.3512. View

van der Linden R, Frenken L, de Geus B, Harmsen M, Ruuls R, Stok W . Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta. 1999; 1431(1):37-46. DOI: 10.1016/s0167-4838(99)00030-8. View

Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Quigley A, Hulsik D . Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS One. 2012; 7(3):e33298. PMC: 3305327. DOI: 10.1371/journal.pone.0033298. View

Greenberg A, Avila D, Hughes M, Hughes A, McKinney E, Flajnik M . A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature. 1995; 374(6518):168-73. DOI: 10.1038/374168a0. View

Holz J . The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2012; 46(3):343-6. DOI: 10.1016/j.transci.2012.03.027. View

Van de Broek B, Devoogdt N, DHollander A, Gijs H, Jans K, Lagae L . Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano. 2011; 5(6):4319-28. DOI: 10.1021/nn1023363. View

10.

Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M . The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015; 17:135. PMC: 4476083. DOI: 10.1186/s13075-015-0651-0. View

11.

Muyldermans S, Atarhouch T, Saldanha J, Barbosa J, HAMERS R . Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994; 7(9):1129-35. DOI: 10.1093/protein/7.9.1129. View

12.

Tang J, Szikra T, Kozorovitskiy Y, Teixiera M, Sabatini B, Roska B . A nanobody-based system using fluorescent proteins as scaffolds for cell-specific gene manipulation. Cell. 2013; 154(4):928-39. PMC: 4096992. DOI: 10.1016/j.cell.2013.07.021. View

13.

Jobling S, Jarman C, Holmberg N, Blake C, Verhoeyen M . Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat Biotechnol. 2002; 21(1):77-80. DOI: 10.1038/nbt772. View

14.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

15.

Muyldermans S, Lauwereys M . Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit. 1999; 12(2):131-40. DOI: 10.1002/(SICI)1099-1352(199903/04)12:2<131::AID-JMR454>3.0.CO;2-M. View

16.

Arbabi Ghahroudi M, Desmyter A, Wyns L, HAMERS R, Muyldermans S . Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997; 414(3):521-6. DOI: 10.1016/s0014-5793(97)01062-4. View

17.

De Genst E, Guilliams T, Wellens J, ODay E, Waudby C, Meehan S . Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J Mol Biol. 2010; 402(2):326-43. DOI: 10.1016/j.jmb.2010.07.001. View

18.

Nguyen-Duc T, Peeters E, Muyldermans S, Charlier D, Hassanzadeh-Ghassabeh G . Nanobody(R)-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites. Nucleic Acids Res. 2013; 41(5):e59. PMC: 3597646. DOI: 10.1093/nar/gks1342. View

19.

Li T, Bourgeois J, Celli S, Glacial F, Le Sourd A, Mecheri S . Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 2012; 26(10):3969-79. DOI: 10.1096/fj.11-201384. View